Cargando…
Delivery of Cancer Therapeutics Using Nanotechnology
Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834952/ https://www.ncbi.nlm.nih.gov/pubmed/24300452 http://dx.doi.org/10.3390/pharmaceutics5020294 |
_version_ | 1782292073752297472 |
---|---|
author | Lim, Eun-Kyung Jang, Eunji Lee, Kwangyeol Haam, Seungjoo Huh, Yong-Min |
author_facet | Lim, Eun-Kyung Jang, Eunji Lee, Kwangyeol Haam, Seungjoo Huh, Yong-Min |
author_sort | Lim, Eun-Kyung |
collection | PubMed |
description | Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems. |
format | Online Article Text |
id | pubmed-3834952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-38349522013-11-21 Delivery of Cancer Therapeutics Using Nanotechnology Lim, Eun-Kyung Jang, Eunji Lee, Kwangyeol Haam, Seungjoo Huh, Yong-Min Pharmaceutics Review Nanoparticles have been investigated as drug carriers, because they provide a great opportunity due to their advantageous features: (i) various formulations using organic/inorganic materials, (ii) easy modification of targeting molecules, drugs or other molecules on them, (iii) effective delivery to target sites, resulting in high therapeutic efficacy and (iv) controlling drug release by external/internal stimuli. Because of these features, therapeutic efficacy can be improved and unwanted side effects can be reduced. Theranostic nanoparticles have been developed by incorporating imaging agents in drug carriers as all-in-one system, which makes it possible to diagnose and treat cancer by monitoring drug delivery behavior simultaneously. Recently, stimuli-responsive, activatable nanomaterials are being applied that are capable of producing chemical or physical changes by external stimuli. By using these nanoparticles, multiple tasks can be carried out simultaneously, e.g., early and accurate diagnosis, efficient cataloguing of patient groups of personalized therapy and real-time monitoring of disease progress. In this paper, we describe various types of nanoparticles for drug delivery systems, as well as theranostic systems. MDPI 2013-05-15 /pmc/articles/PMC3834952/ /pubmed/24300452 http://dx.doi.org/10.3390/pharmaceutics5020294 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Lim, Eun-Kyung Jang, Eunji Lee, Kwangyeol Haam, Seungjoo Huh, Yong-Min Delivery of Cancer Therapeutics Using Nanotechnology |
title | Delivery of Cancer Therapeutics Using Nanotechnology |
title_full | Delivery of Cancer Therapeutics Using Nanotechnology |
title_fullStr | Delivery of Cancer Therapeutics Using Nanotechnology |
title_full_unstemmed | Delivery of Cancer Therapeutics Using Nanotechnology |
title_short | Delivery of Cancer Therapeutics Using Nanotechnology |
title_sort | delivery of cancer therapeutics using nanotechnology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834952/ https://www.ncbi.nlm.nih.gov/pubmed/24300452 http://dx.doi.org/10.3390/pharmaceutics5020294 |
work_keys_str_mv | AT limeunkyung deliveryofcancertherapeuticsusingnanotechnology AT jangeunji deliveryofcancertherapeuticsusingnanotechnology AT leekwangyeol deliveryofcancertherapeuticsusingnanotechnology AT haamseungjoo deliveryofcancertherapeuticsusingnanotechnology AT huhyongmin deliveryofcancertherapeuticsusingnanotechnology |